LONDON--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, and NHS England today announced the availability of the easy ...
EDINBURGH, Scotland--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced today the publication of a ...
Dexcom has been abuzz this year amid the European approval—and submission for FDA approval in the U.S.—for its next-generation G7 continuous glucose monitoring system, which promises more accurate ...
Dexcom has launched its ONE+ continuous glucose monitoring (CGM) device in the UK, alongside a report that details high rates of anxiety and depression amongst type 2 diabetes (T2D) patients. The ...
Now the longest lasting and most accurate CGM system, Dexcom G7 15 Day gives users the knowledge to better control diabetes. Dexcom G7 15 Day builds on the performance of Dexcom CGM, which is ...
Dexcom G7 Continuous Glucose Monitoring System Will Be Available to Medicare Beneficiaries at Launch
SAN DIEGO--(BUSINESS WIRE)-- Dexcom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today its next-generation Dexcom G7 CGM System ...
DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System for people over the age of 18 with diabetes will ...
Partnership will enable two-way data flow between Dexcom glucose biosensors and apps and Oura Ring and the Oura App, providing a first-of-its-kind metabolic health management experience Co-marketing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback